×
Concentras Parent Price to Free Cash Flow Ratio 2025-2024 | CON
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
PE Ratio
P/S Ratio
Price/Book Ratio
Price-FCF Ratio
Net Worth
Concentras Parent price to free cash flow ratio from 2025 to 2024. Price to free cash flow ratio can be defined as
View More
Concentras Parent Price to Free Cash Flow Ratio 2025-2024 | CON
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
PE Ratio
P/S Ratio
Price/Book Ratio
Price-FCF Ratio
Net Worth
Concentras Parent price to free cash flow ratio from 2025 to 2024. Price to free cash flow ratio can be defined as
Related Stocks
Company Name
Market
Cap
Elevance Health (ELV)
$126B
Cencora (COR)
$46.2B
ICON (ICLR)
$24.1B
DiDi Global (DIDIY)
$18.8B
Avantor (AVTR)
$18.3B
Natera (NTRA)
$15.7B
Revvity (RVTY)
$15.1B
Viatris (VTRS)
$14.1B
CochLear (CHEOY)
$12.8B
Solventum (SOLV)
$12.5B
Medpace Holdings (MEDP)
$11B
Charles River Laboratories (CRL)
$10.6B
Sonic Healthcare (SKHHY)
$8.9B
Doximity (DOCS)
$7.5B
HealthEquity (HQY)
$6.9B
Bausch + Lomb (BLCO)
$6.5B
PACS (PACS)
$6.2B
Organon (OGN)
$5.3B
Life Times (LTH)
$4.9B
Sotera Health (SHC)
$4.7B
Surgery Partners (SGRY)
$4B
GoodRx Holdings (GDRX)
$2.9B
BrightSpring Health Services (BTSG)
$2.5B
Ardent Health Partners (ARDT)
$2.5B
Progyny (PGNY)
$2.2B
Alignment Healthcare (ALHC)
$2.2B
Premier (PINC)
$2.1B
Ryman Healthcare (RYHTY)
$2B
AMN Healthcare Services Inc (AMN)
$1.8B
CareDx (CDNA)
$1.6B